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Introduction
Carbapenems, such as imipenem and meropenem,
remain one of the best drugs to treat infections caused
by Pseudomonas aeruginosa. Increasing usage of
these drugs and other expanded-spectrum antibiotics
has resulted in the development of carbapenem-resist-
ant P. aeruginosa. The clinical utility of these antimi-
crobials is under the thread with the emergence of
acquired genes for carbapenemases, particularly those
coding metallo-β-lactamases (MBLs). Acquired MBLs
expression in gram-negative pathogens is becoming a
therapeutic challenge since these enzymes are capable
hydrolyzing all β-lactams except the monobactams
[5,6].
The genes responsible for the production of MBLs
are typically part of an integron structure and carried
on transferable plasmids but can also be part of the
chromosome [8].  The blaIMP genes were often located in
Pseudomonas aeruginosa rods on largesize plasmids.
Acquisition of blaIMP genes is not always followed by
expression of a high level of resistance to carbapenems,
because several isolates carrying the cryptic blaIMP genes
demonstrated low-level carbapenem resistance [4].
During the past decade, a number of acquired MBLs
have been identified in Gram-negative pathogens and
were categorized into 2 major types: IMP and VIM
[6,12]. 
IMP-1 was the first acquired carbapenemases  detect-
ed among Pseudomonas aeruginosa in Japan [15]; since
them, numerous IMP-type variants have been described
in Pseudomonas aeruginosa mainly in Asian and some
American and European regions [3,9,13].
The aim of this study was to determine the preva-
lence of blaIMP genes among multidrug-resistant
Pseudomonas aeruginosa strains isolated from various
clinical specimens in the University Hospital in Bia-
lystok (Poland).
In this work we report the first PCR detection of
IMP-type plasmid-mediated MBLs genes in two mul-
tidrug-resistant isolates of Pseudomonas aeruginosa.
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with the production of a metallo-β-lactamases. Plasmids DNA probes were used to investigate the presence of genes cod-
ing for IMP-type enzymes. PCR experiments revealed that blaIMP genes were present in two isolates of Pseudomonas aerug-
inosa (MIC >32 µg/mL for both carbapenems).
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Materials and methods
Bacterial strains. Seven carbapenem-resistant strains of Pseu-
domonas aeruginosa used in this study were isolated from clinical
samples in the University Hospital in Bialystok (Poland). Bacteri-
al identification was performed using conventional methods and
VITEK cards for identification (GNI) in VITEK 1 automated sys-
tem (bioMérieux, Marcy l'Etoile, France). The identification was
repeated by using API 20NE test and ATB system (bioMérieux,
Marcy l'Etoile, France).
Antibiotics susceptibility. The VITEK sensitivity test card
(GNS-650) was used for determination of the selected antibiotics
susceptibility. The following antibiotics were tested: imipenem,
amikacin, aztreonam, cefepime, ceftotaxime, ceftazidime,
ciprofloxacin, gentamicin, piperacillin/tazobactam and ticar-
cillin/clavulanic acid. Results were interpreted by Vitek software
version SYS R06.06.
The susceptibility to carbapenems was retested using the
Etest (AB Biodisk, Solna, Sweden) on Muller-Hinton agar
(Oxoid, Basingstoke, UK) according manufacturer's instructions.
Resistance to antibiotics was defined according to the Clinical
and Laboratory Standards Institute (formerly NCCLS) recom-
mendations [1]. 
P. aeruginosa ATCC 27853, Escherichia coli ATCC 25922,
and Escherichia coli ATCC 35218 were used as reference strains.
Screening of MBL-producing isolates. MBLs production was
screened by the Etest MBL strips (AB Biodisk, Solna, Sweden)
technique. Results were considered as positive when the MIC
(minmal inhibitory concentration) ratio of imipenem/imipenem
plus EDTA was ≥8. The presence of phantom zone (or deformation
of imipenem ellipse) was also considered as indicative of MBL
production [13].
Plasmids DNA isolation. Plasmids DNA extractions of P. aerugi-
nosa isolates were performed with the Plasmid Mini (A&A
Biotechnology, Gdynia, Poland) according to the manufacturer's
instructions.
Molecular detection of the blaIMP genes. Detection of blaIMP
genes was performed using PCR assays with previously
described primers [10]. Primer pair was used to amplify a 587 bp
fragment of genes encoding the IMP-1 like enzymes. PCR ampli-
fication was performed in 25 μl volume with the Cyclone 96
(PEQLAB Biotechnology, GmbH) thermal cycler. The PCR mix-
tures contained: 25 pmol of each primer, 1× reaction buffer, 2
mM MgCl2, 1 l of dNTPs, 0.5U of Delta 2 DNA polymerase
(DNA-Gdansk II, Gdansk, Poland), 2 l of template DNA and ultra
pure H2O to final volume. The cycling parameters of amplifica-
tion were: initial denaturation at 94°5 C for 2.5 min; denaturation
at 94°C for 40 s, annealing at 57°C for 40 s, and extension at
72°C for 60s repeated for 35 cycles. The final elongation step
was at 72°C for 4 min.
Detection of PCR products. Products of PCR were analyzed by
electrophoresis at 5V/cm for 90 min in 1.8% agarose gel contain-
ing 0.5 µg/ml ethidium bromide in TBE buffer and photographed
on a UV transilluminator. The sizes of the fragments produced in
the amplifications were calculated from their positions relative to
the positions of the molecular weight marker.
Results and discussion
Production of MBLs represents an important mecha-
nism of resistance to carbapenems and other β-lactams
among P. aeruginosa rods. Resistance to carbapenems
in nosomical populations of P. aeruginosa in Poland
have been increasing in recent years and indicated
clearly those MBLs have started to constitute a coun-
trywide problem [9,11].
All of P. aeruginosa isolates tested in this study
was carbapenem-resistant, but the levels of resistance
were diverse (Table 1). A comparison of MICs of 2
MBLs-positive (MIC, >32 mg/L for imipenem and
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Table 1. Characteristics of multidrug-resistant (MDR) Pseudomonas aeruginosa strains. 
Abbreviations:  aIMI, imipenem; AZM, aztreonam; FEP, cefepime; TAX, cefotaxime; TAZ, ceftazidime; CIP, ciprofloxacin; AN, amikacin; GM, gentam-
icin; TZP, pipercillin/tazobactam; TCC, ticarcillin/clavulanic acid; bMIC (mg/L): MEM, meropenem; IP, imipenem.
meropenem) isolates with five MBLs-negative (MIC,
16-32 mg/L) isolates suggested presence different
mechanisms resistance to carbapenems.  Mechanisms
low-level resistance to carbapenems (MIC, 832 mg/L)
in P. aeruginosa are often associated with reduced
uptake as a results loss of the OprD porin combined
with de-repression of the chromosomal AmpC β-lacta-
mase gene or by over-expression of an efflux pump
system [5,11].
Only one isolate (Psa-1) was susceptible to amino-
glycoside antibiotics, intermediate to cefepime, cef-
tazidime and ciprofloxacin. Two (Psa-4 and Psa-6) of
MBLs-negative was susceptible to piperacillin with
tazobactam (MIC, 64 mg/L).
Screening by the Etest MBL strips showed possi-
bility to production of MBLs in two (Psa-5 and Psa-7)
isolates. The same isolates were found to be positive in
PCRs for the presence of the blaIMP gene (Fig.1).
In our study blaIMP gene was carried on a plasmids
DNA. The two of blaIMP - positive P. aeruginosa
strains were detected in different patients in urine.
Broad-spectrum β-lactams usually administrated to
inpatients through drip infusion, and they are mostly
excreted in urine without being dissolved modified.
Since these agents tend to be highly condensed in urine
and bacteria surviving in the urinary tract must acquire
high-level resistance to these antibiotics.
Despite the low number of isolates, this study is
the first report of the presence of IMP-type carbapen-
emases in Poland. Further investigations are neces-
sary to gain a better understanding of epidemiology
and genetic background of these enzymes (study
ongoing).
Long-term hospitalisation, indwelling urinary
catheters, and long-term antibiotic use (in particular
of carbapenems) are the possible risk factors for colo-
nization and/or infection such pathogens as MBLs-
positive Pseudomonas aeruginosa. In absence of
novel antibiotics for the treatment of infections caused
by multidrug-resistant gram-negative bacteria in the
near future, uncontrolled spread of MBLs producers
may lead to treatment failures with increased morbid-
ity and mortality. Appropriate therapeutic protocols
and a regular screening/monitoring system should be
established to prevent the wider spread of this worri-
some resistance determinant.
Understanding the epidemiology and mechanisms
for dissemination of MBL-producing strains is an essen-
tial step to control these phenomena. In Europe,
although infections caused by VIM-producing P. aerug-
inosa have been observed for almost a decade, little is
still known about the epidemiological relation between
IMP-producing isolates from different regions.
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